Shows promise in stem cell model of retinitis pigmentosa
Although the 2017 FDA approval of Spark Therapeutics’ gene therapy Luxturna was considered a triumph for people with inherited eye disease, the product can only be used in patients with mutations in the RPE65 gene. Now, scientists in the United Kingdom say they’ve developed a gene therapy technique that could help a larger population of patients with retinitis pigmentosa.
Scientists at Trinity College Dublin and University College London zeroed in on the RP2 gene, which can become mutated to cause a number of forms of retinitis pigmentosa. Functional copies of the RP2 gene delivered to “mini retinas” were able to pump out a vital protein called rhodopsin, the researchers reported (PDF) in the journal Stem Cell Reports.
The mini retinas used in the study were three-dimensional organoids made from induced pluripotent stem cells and stem cells taken from patients with RP2-mutated retinitis pigmentosa. The organoids started losing the rod photoreceptor cells needed for proper vision at day 150. The gene therapy prevented that degeneration, the researchers said.
To continue reading the article, click here.